Multiple Myeloma Refractory research hub
5 indexed studies · 5 currently recruiting
- recruitingPHASE2
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
This study is testing a new combination of medicines – inobrodib, pomalidomide, and dexamethasone – for people in the UK with multiple myeloma that has come back and is no longer responding to usual treatments. The aim is to see how well these medicines work together and what side effects they might cause.
United States · United Kingdom - recruitingNA
Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma
This study looks at adding early support care for people with multiple myeloma or aggressive lymphoma. It wants to see if this helps improve their well-being, mood, and how they feel about their care, compared to standard care alone.
Canada - recruitingPHASE1
A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies
This early-stage study is testing a new cell therapy called MDC-CAR-BCMA001. It aims to find the safest dose for people with certain types of blood cancers, like some lymphomas and multiple myeloma, that have come back or not responded to other treatments.
Germany - not yet recruitingPHASE1
Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma
This study is testing a new turmeric-based drug called LipoCurc for people with multiple myeloma that has come back or isn't responding to other treatments. The main goal is to find a safe dose and see what side effects it might cause.
Canada - recruitingPHASE4
Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
This study looks at how to best prevent infections in people with multiple myeloma receiving new treatments called BCMA-directed T-cell engagers. It compares two different amounts of immunoglobulin support to see which is better at reducing severe infections.
Canada